Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Position Lessened by Sage Rhino Capital LLC

Sage Rhino Capital LLC trimmed its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 8.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 553 shares of the pharmaceutical company’s stock after selling 54 shares during the period. Sage Rhino Capital LLC’s holdings in Vertex Pharmaceuticals were worth $225,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of Vertex Pharmaceuticals by 0.4% in the third quarter. Vanguard Group Inc. now owns 21,983,356 shares of the pharmaceutical company’s stock worth $7,644,492,000 after purchasing an additional 87,397 shares during the period. Jennison Associates LLC raised its stake in shares of Vertex Pharmaceuticals by 3.9% in the fourth quarter. Jennison Associates LLC now owns 3,944,913 shares of the pharmaceutical company’s stock valued at $1,605,146,000 after acquiring an additional 147,248 shares during the last quarter. Morgan Stanley raised its position in Vertex Pharmaceuticals by 3.2% in the 3rd quarter. Morgan Stanley now owns 2,870,101 shares of the pharmaceutical company’s stock worth $998,050,000 after purchasing an additional 89,217 shares during the last quarter. Northern Trust Corp raised its position in Vertex Pharmaceuticals by 4.9% in the 3rd quarter. Northern Trust Corp now owns 2,813,563 shares of the pharmaceutical company’s stock worth $978,388,000 after purchasing an additional 131,539 shares during the last quarter. Finally, Invesco Ltd. raised its position in Vertex Pharmaceuticals by 3.5% in the 3rd quarter. Invesco Ltd. now owns 2,016,780 shares of the pharmaceutical company’s stock worth $701,315,000 after purchasing an additional 67,451 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors.

Insider Transactions at Vertex Pharmaceuticals

In other news, EVP Ourania Tatsis sold 354 shares of the business’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $425.70, for a total transaction of $150,697.80. Following the completion of the sale, the executive vice president now directly owns 55,804 shares of the company’s stock, valued at $23,755,762.80. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 354 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $425.70, for a total value of $150,697.80. Following the completion of the sale, the executive vice president now directly owns 55,804 shares of the company’s stock, valued at approximately $23,755,762.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Amit Sachdev sold 3,222 shares of the company’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the completion of the sale, the executive vice president now directly owns 74,364 shares of the company’s stock, valued at $31,250,727.36. The disclosure for this sale can be found here. Insiders sold a total of 12,381 shares of company stock valued at $5,203,249 over the last three months. Corporate insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Trading Up 0.2 %

VRTX stock traded up $0.71 during midday trading on Wednesday, hitting $393.52. The stock had a trading volume of 65,081 shares, compared to its average volume of 1,212,314. The business has a fifty day moving average price of $410.52 and a two-hundred day moving average price of $399.52. Vertex Pharmaceuticals Incorporated has a 1-year low of $320.01 and a 1-year high of $448.40. The firm has a market cap of $101.71 billion, a P/E ratio of 28.28, a price-to-earnings-growth ratio of 1.87 and a beta of 0.35. The company has a current ratio of 3.99, a quick ratio of 3.78 and a debt-to-equity ratio of 0.02.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share for the quarter, beating the consensus estimate of $3.85 by $0.35. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The firm had revenue of $2.52 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same quarter in the prior year, the business earned $3.33 earnings per share. On average, sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. William Blair restated an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 6th. Barclays boosted their price objective on shares of Vertex Pharmaceuticals from $446.00 to $472.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. UBS Group dropped their target price on shares of Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating for the company in a research report on Wednesday, April 17th. Canaccord Genuity Group cut shares of Vertex Pharmaceuticals from a “hold” rating to a “sell” rating and upped their target price for the company from $332.00 to $379.00 in a research report on Wednesday, January 24th. Finally, Truist Financial upped their target price on shares of Vertex Pharmaceuticals from $456.00 to $508.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $429.45.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.